Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. director William J. Link reported an exercise of 201 Restricted Stock Units into 201 shares of common stock on September 15, 2026, leaving 605 RSUs outstanding. On the same date he reported sales of 12,500 common shares at weighted average prices around the high-$70s under a Rule 10b5-1 trading plan adopted on September 8, 2025.
Tarsus Pharmaceuticals, Inc. (TARS) received a notice under Rule 144 that director J. Link plans to sell 12,500 shares of common stock through Merrill Lynch on or about September 15, 2026 on Nasdaq. The shares were acquired on January 10, 2017 via a stock option exercise paid in cash.
Tarsus Pharmaceuticals, Inc. (TARS) completed its acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, merging Apex 2026 Merger Sub into Alkeus, which now operates as a wholly owned subsidiary. Tarsus paid $270,000,000 in up-front cash, subject to customary and post-closing adjustments, and issued 2,908,692 shares of common stock as additional up-front consideration to Alkeus equityholders.
Alkeus holders are also eligible for up to $350,000,000 in future milestone payments, including $250,000,000 payable in cash and/or Tarsus common stock upon U.S. regulatory approval of an Alkeus product, and $100,000,000 in cash upon the first U.S. sale of an Alkeus product, plus tiered low-to-mid single-digit revenue sharing on future annual worldwide gildeuretinol (ALK-001) net sales. Tarsus gains worldwide rights to ALK-001, an oral Phase 3 investigational therapy for Stargardt disease, which has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA and is being studied in the NORTHSTAR Phase 3 trial with topline data anticipated in 2029.
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock on September 4, 2026 in transactions reported as sales in the open market or in private transactions. The sales were executed under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025, at weighted average prices of about $90.27 and $91.27 per share, with individual trades in ranges from $90.00 to $90.91 and from $91.06 to $91.45. Following these transactions, he is reported to hold 33,421 shares of common stock directly.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold an aggregate of 13,953 shares of common stock on September 4, 2026. The sales included both directly held shares and shares held through a spouse’s Roth IRA, and were executed in the open market under pre-arranged Rule 10b5-1 trading plans adopted on May 29, 2026 and June 1, 2026. Following these transactions, an additional 12,040 shares of common stock are reported as indirectly held through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Operating Officer Neervannan Seshadri sold 4,564 shares of common stock on September 4, 2026 at $85.00 per share in an open-market transaction effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following this sale, he directly holds 78,532 shares and is also reported with an indirect balance of 475 shares related to his daughter, for which beneficial ownership is disclaimed.
Tarsus Pharmaceuticals, Inc. (TARS) has an officer, Bobak Azamian, filing a Form 144 notice covering a potential sale of up to 10,000 shares of common stock through Merrill Lynch on Nasdaq. These shares were acquired on January 13, 2017 in a private placement. In the prior three months, the Bobak Azamian Living Trust reported two sales of 10,000 shares each.
Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice indicating an intention to sell restricted or control securities. The notice covers a planned sale of 3,180 shares of Tarsus common stock through Fidelity Brokerage Services LLC on Nasdaq. The filing states that the shares are in the account of Stephen H. Lin, the spouse of company officer Elizabeth Yeu-Lin. It also notes prior sales from the same account over the past three months and lists 43,882,996 Tarsus common shares outstanding as of September 4, 2026.
Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice for a planned resale of common stock by company officer Elizabeth Yeu-Lin. The notice covers 10,773 shares of common stock, acquired in open market purchases on September 14, 2022 and August 15, 2023, with an aggregate market value of $942,635.00 as of the notice.
The filing states that Tarsus had 43,882,996 shares of common stock outstanding. It also lists sales during the past three months totaling 11,578 shares of common stock for approximately $897,989.86, including sales from the account of the officer’s spouse, which are aggregated under Rule 144.
Tarsus Pharmaceuticals, Inc. (TARS) has a notice under Rule 144 indicating that officer Seshadri Neervannan plans a potential sale of up to 4,564 shares of common stock through Fidelity Brokerage Services LLC. The planned sale relates to shares acquired via restricted stock vesting and an employee stock purchase plan in 2023.
The notice reports an aggregate market value of about $387,940 for these shares and lists 43,882,996 common shares outstanding, providing context for the size of the proposed sale.